Currently MC at max dilution about $ 40m.Even if we ignore cash...

Currently MC at max dilution about $ 40m.

Even if we ignore cash at hand of $ 5-8m, the 3 platforms are valued at almost nothing with 2 clinical trials showing safety and efficacy.

Based on recent US deals, that could be valued at US $ 1b, yes 1b!!!!!!!!!!!!!!!!


CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of
patients with solid tumours. CHM 1101 is currently being studied in a phase 1 clinical trial in
recurrent/ progressive glioblastoma. Initial positive data has been presented on patients treated
in the first two dose levels of the trial. A 2nd CLTX CAR T phase 1 clinical trial is planned to begin
in metastatic melanoma with future expansion to additional solid tumours.

CHM 2101 (CDH17 CAR T) is a novel, 3rd generation CDH17 CAR T invented at the worldrenowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101
was published in March 2022 in Nature Cancer. CHM 2101 (CDH17 CAR T) is currently in
preclinical development with a planned phase 1 clinical trial in neuroendocrine tumours,
colorectal, gastroesophageal and gastric cancer.

CHM 0201 (CORE-NK platform) is a clinically validated, off the shelf natural killer (NK) cell
platform. Data from the complete phase 1 clinical trial was published in March 2022,
demonstrating safety and efficacy in blood cancers and solid tumours. From the CORE-NK
platform, Chimeric will initiate development of four new next generation NK and CAR NK assets
with plans for phase 1 clinical trials in solid tumours and blood cancers.

Not sure why the selling BOT is in over drive. At IMU the manipulation makes sense as the same entity buys and sells to itself, programmed to accumulate. But here it seems it just serves one purpose, frustrating holders. Maybe they are catching retail shares not by buying up, as happen at IMU, but by just getting filled.

Anyway, totally undervalued with having a $30m funding arrangement in place. Still catching some here and there and not complaining about lower prices as I accumulate too but can understand holder's frustration and them blaming management. But have a look at IMU, common sense will prevail over time.

ST pain, LT gain.

GLTA